Risk of malignant neoplasms of tacrolimus in kidney transplant patients: a retrospective cohort study conducted using the Japanese National Database of Health Insurance Claims
Retrospective cohort study assesses malignant neoplasms risk in kidney transplant patients using tacrolimus and cyclosporine A, suggesting no added risk with tacrolimus.
Key Points
Malignant neoplasms incidence was 11% among kidney transplant patients, with the digestive organs being most affected.
There was no significant difference in malignant neoplasms incidence between tacrolimus (TAC) and cyclosporine A (CyA) users, with a hazards ratio of 0.97.
This retrospective cohort study utilized data from the Japanese National Database covering 99% of kidney transplant patients, providing comprehensive insights.
The results indicate that tacrolimus is not linked to a higher risk of malignant neoplasms compared to cyclosporine A in late post-transplant care.